ArticleTranslational stroke research2026
Phenotype-Aligned Metabolomics Identifies Plasma Arginine as a Candidate Predictor of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage.
Article in Translational stroke research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Delayed cerebral ischemia (DCI) affects approximately 30% of aneurysmal subarachnoid hemorrhage (aSAH) survivors and is a leading cause of morbidity and mortality post-aSAH. Current risk assessment relies on radiographic severity scores that stratify populations based on hemorrhage characteristics but cannot predict DCI onset for individual patients. No plasma-based biomarkers for DCI prediction currently exist. We used liquid chromatography – mass spectrometry to perform plasma metabolomics in 60 aSAH patients (50% female, 30 DCI, 30 No-DCI) with longitudinal sampling until 7 days post-aSAH. Samples were retrospectively aligned to individual DCI onset times per patient, isolating 24–48 h and 48–72 h pre-event windows. Arginine emerged as the sole FDR-significant metabolite 24–48 h before DCI (q = 0.022, 39% depletion) and ranked #1 of 2,022 metabolites across three statistical methods (Student’s t-test, Welch’s t-test, Mann-Whitney U test, p = 10⁻⁵ to 10⁻⁴). Zero metabolites achieved FDR significance at 48–72 h, confirming temporal specificity. Independent logistic regression validated predictive performance (odds ratio 0.22, p = 0.001, AUC 0.808, 95% CI: 0.647–0.945), outperforming modified Fisher radiographic score (AUC 0.718, 95% CI: 0.593–0.830). The combination model of arginine and modified Fisher score performed best with AUC 0.856 (95% CI: 0.733–0.955), with arginine as the dominant factor. Mechanistic investigation revealed FDR-significant depletion of arginine/ornithine (q = 0.011) and glutamine/glutamate ratios (q = 0.011), consistent with increased arginase activity competing with nitric oxide synthesis. Plasma arginine represents a candidate single-molecule biomarker for DCI with a clinically actionable pre-event detection window, pending prospective validation. Temporal alignment to individual DCI onsets enabled detection of pre-event metabolic changes 24–48 h before symptom onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.